Advertisement

International Journal of Clinical Pharmacy

, Volume 37, Issue 1, pp 86–93 | Cite as

Factors affecting nebulised medicine adherence in adult patients with cystic fibrosis: a qualitative study

  • Alice Hogan
  • Mary-Ann Bonney
  • Jo-anne Brien
  • Rita Karamy
  • Parisa AslaniEmail author
Research Article

Abstract

Background Nebulised medicines contribute to the high treatment burden experienced by patients with cystic fibrosis (CF). Objectives This study explored experiences of adult patients with CF when using nebulised medicines, factors impacting on their adherence to nebulised therapy and strategies they used to facilitate adherence. Setting Community setting, in Sydney, Australia. Methods Ten patients with CF were recruited through a CF patient organisation. Semi-structured face-to-face interviews were conducted, addressing the study objectives. Interviews were audio-recorded, transcribed verbatim and content analysed for anticipated and emergent themes. Main outcome measure Experiences with using nebulised medicines; and barriers and facilitators of adherence to nebulised medicines. Results Participants’ age ranged from 22 to 45 years, with half being male. Four broad themes (with more specific sub-themes) were identified from the interviews: experiences with using nebulised medicines (cleaning nebuliser, time taken to use nebuliser medicine, flexibility in use of nebuliser); feelings about using nebulised medicines (necessary/important, dislike, part of life); factors impacting non-adherence (time consuming therapy, side effects/effects of medicine, work/social demands, lack of perceived importance); factors and strategies facilitating adherence (perceived medicine importance, habit/routine, support, health benefits, technology/medicine dose form, timetabling). Conclusions Nebulised therapy for cystic fibrosis patients takes a substantial amount of time, with patients trying to alter their routine to incorporate nebulising into their daily lives. However there are still many factors that lead to low adherence, including work/social demands and travelling. Patients balance the necessity for nebulised therapy against the barriers, and engage in intentional non-adherence at times. Future strategies and resources should target and address specific factors identified by patients with CF as being important and impacting their adherence to nebulised medicines.

Keywords

Barriers Cystic fibrosis Facilitators Medication adherence 

Notes

Acknowledgments

The authors acknowledge and thank the individuals that gave their time to be interviewed for this study, and the staff of Cystic Fibrosis New South Wales, in particular Alex Huntir and Miraa Best, for assistance with recruiting the participants.

Funding

Study participant’s travel costs were reimbursed by Novartis Pharmaceuticals Australia.

Conflicts of interest

AH, J-AB and PA have no conflicts of interest to declare. MB and RK are employees of Novartis Pharmaceuticals Australia; Novartis is the manufacturer of two forms of inhaled tobramycin for patients with cystic fibrosis.

References

  1. 1.
    Seeley RR, Stephens TD, Tate P. Essentials of anatomy and physiology. 6th ed. New York: McGraw-Hill; 2007. ISBN 9781133018216.Google Scholar
  2. 2.
    Accurso FJ. Update in Cystic Fibrosis 2007. Am J Respir Crit Care Med. 2008;177:1058–61.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Boyle MP. So many drugs, so little time: the future challenge of cystic fibrosis care. Chest. 2003;123:3–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;8:91–6.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Flume PA, O’Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Resp Crit Care Med. 2008;176:957–69.CrossRefGoogle Scholar
  6. 6.
    Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med. 2011;11:1–6.CrossRefGoogle Scholar
  7. 7.
    Burrows JA, Bunting JP, Masel PJ, Bell SC. Nebulised dornase alpha: adherence in adults with cystic fibrosis. J Cyst Fibros. 2002;1:255–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10:258–64.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Dziuban EJ, Saab-Abazeed L, Chaudhry SR, Streetman DS, Nasr SZ. Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatr Pulmonol. 2010;45:450–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Bregnballe V, Schiotz PO, Boisen KA, Pressler T, Thastum M. Barriers to adherence in adolescents and young adults with cystic fibrosis: a questionnaire study in young patients and their parents. Patient Prefer Adherence. 2011;5:507–15.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol. 2006;31:846–58.PubMedCrossRefGoogle Scholar
  12. 12.
    DeLambo KE, Ievers-Landis CE, Drotar D, Quittner AL. Association of observed family relationship quality and problem-solving skills with treatment adherence in older children and adolescents with cystic fibrosis. J Pediatr Psychol. 2004;29:343–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Cystic Fibrosis in Australia 2011. 14th annual report from the Australian Cystic Fibrosis Data Registry. Sydney: Cystic Fibrosis Australia, 2012. ISSN 1447–3933.Google Scholar
  14. 14.
    Plummer A, Costall B, Torry B. Factors affecting adherence in adults with cystic fibrosis. Pharm Pract. 2008;18:52–6.Google Scholar
  15. 15.
    George M, Rand-Giovannetti D, Eakin MN, Borrelli B, Zettler M, Riekert KA. Perceptions of barriers and facilitators: self-management decisions by older adolescents and adults with CF. J Cyst Fibros. 2010;9:425–32.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Conway SP, Pond MN, Hamnett T, Watson A. Compliance with treatment in adult patients with cystic fibrosis. Thorax. 1996;51:29–33.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Zindani GN, Streetman DD, Streetman DS, Nasr SZ. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health. 2006;38:13–7.PubMedCrossRefGoogle Scholar
  18. 18.
    DiCicco-Bloom B, Crabtree BF. The qualitative research interview. Med Educ. 2006;40:314–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Brod M, Tesler LE, Christensen TL. Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res. 2009;18:1263–78.PubMedCrossRefGoogle Scholar
  20. 20.
    Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing qualitative data. BMJ. 2000;320:114–6.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Rosenstock I. The health belief model and preventative health behaviour. Health Educ Monogr. 1974;2:354–86.Google Scholar
  22. 22.
    Ajzen I, Fishbein M. Understanding attitudes and predicting social behaviour. Englewood Cliffs: Prentice-Hall; 1980. ISBN 0139364358.Google Scholar
  23. 23.
    Ajzen I. From intentions to actions: a theory of planned behaviour. In: Kuhl J, Beckmann J, editors. Action-control: from cognition to behaviour. Heidelberg: Springer; 1985. ISBN 038713445X.Google Scholar
  24. 24.
    Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cognit Ther Res. 1992;16(2):143–63.CrossRefGoogle Scholar
  25. 25.
    Leventhal H, Benyamini Y, Brownlee S, Diefenbach D, Leventhal EA, Patrick-Miller L, Robitaille C. Illness representations: theoretical foundations. In: Petrie KJ, Weinman J, editors. Perceptions of health and illness: current research and applications. London: Harwood Academic; 1997. p. 19–46. ISBN 905702103X.Google Scholar
  26. 26.
    Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1–24.CrossRefGoogle Scholar
  27. 27.
    Hofmann T. New developments in inhaled antibiotics for the treatment of Pseudomonas aeruginosa. Curr Pharm Des. 2012;18:683–95.PubMedCrossRefGoogle Scholar
  28. 28.
    Latchford G, Duff A, Quinn J, Conway S, Conner M. Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns. 2009;75:141–4.PubMedCrossRefGoogle Scholar
  29. 29.
    McNamara PS, McCormack P, McDonald AJ, Heaf L, Southern KW. Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. J Cyst Fibros. 2009;8:258–63.PubMedCrossRefGoogle Scholar
  30. 30.
    Harrison M, McCarthy M, Fleming C, et al. Improved tolerability, adherence and reduced intravenous (IV) antibiotic usage in CF patients receiving inhaled versus nebulised antibiotic prophylaxis. A real world comparison of tobramycin inhaled powder (TIP) and tobramycin inhaled solution (TIS). J Cyst Fibros. 2013;12(Suppl 1):S67.CrossRefGoogle Scholar
  31. 31.
    Nash E, Ahitan B, Brown C, et al. Comparison of pharmacy prescription refill frequency in CF adults before and after switching from tobramycin inhalation solution (TIS) to TOBI Podhaler—’Real world’ evidence of improved adherence. J Cyst Fibros. 2013;12(Suppl 1):S65.CrossRefGoogle Scholar
  32. 32.
    White T, Miller J, Smith GL, McMahon WM. Adherence and psychopathology in children and adolescents with cystic fibrosis. Eur Child Adolesc Psychiatry. 2009;18:96–104.PubMedCrossRefGoogle Scholar
  33. 33.
    Kettler LJ, Sawyer SM, Winefield HR, Greville HW. Determinants of adherence in adults with cystic fibrosis. Thorax. 2002;57:459–64.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  • Alice Hogan
    • 1
  • Mary-Ann Bonney
    • 2
  • Jo-anne Brien
    • 1
    • 3
  • Rita Karamy
    • 2
  • Parisa Aslani
    • 1
    Email author
  1. 1.Faculty of Pharmacy, Pharmacy and Bank Building A15The University of SydneyBroadwayAustralia
  2. 2.Novartis Pharmaceuticals AustraliaNorth RydeAustralia
  3. 3.St Vincent’s Hospital Clinical School (UNSW)St Vincent’s HospitalDarlinghurstAustralia

Personalised recommendations